Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial.
Yoshida EM, Marotta PJ, Greig PD, Kneteman NM, Marleau D, Cantarovich M, Peltekian KM, Lilly LB, Scudamore CH, Bain VG, Wall WJ, Roy A, Balshaw RF, Barkun JS. Yoshida EM, et al. Among authors: balshaw rf. Liver Transpl. 2005 Sep;11(9):1064-72. doi: 10.1002/lt.20490. Liver Transpl. 2005. PMID: 16123958 Free article. Clinical Trial.
Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alpha-2a plus ribavirin.
Bain VG, Lee SS, Peltekian K, Yoshida EM, Deschênes M, Sherman M, Bailey R, Witt-Sullivan H, Balshaw R, Krajden M; Canadian PEGASYS Study Group. Bain VG, et al. Aliment Pharmacol Ther. 2008 Jul;28(1):43-50. doi: 10.1111/j.1365-2036.2008.03705.x. Epub 2008 Apr 7. Aliment Pharmacol Ther. 2008. PMID: 18397386 Clinical Trial.
Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3.
Powis J, Peltekian KM, Lee SS, Sherman M, Bain VG, Cooper C, Krajden M, Deschenes M, Balshaw RF, Heathcote EJ, Yoshida EM; Canadian Pegasys Study Group. Powis J, et al. Among authors: balshaw rf. J Viral Hepat. 2008 Jan;15(1):52-7. doi: 10.1111/j.1365-2893.2007.00889.x. J Viral Hepat. 2008. PMID: 18088245 Free PMC article. Clinical Trial.
Identifying HCV genotype 1 patients at risk of relapse.
Deschênes M, Bain VG, Lee SS, Sherman M, Cooper CL, Yoshida EM, Marotta PJ, Krajden M, Usaty C, Balshaw R, Peltekian KM; Canadian Pegasys Study Group. Deschênes M, et al. Eur J Gastroenterol Hepatol. 2010 May;22(5):546-51. doi: 10.1097/MEG.0b013e32832d237d. Eur J Gastroenterol Hepatol. 2010. PMID: 20216320
127 results